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Myc activity is emerging as a key element in acquisi-
tion and maintenance of stem cell properties. We
have previously shown that c-Myc deficiency results
in accumulation of defective hematopoietic stem
cells (HSCs) due to niche-dependent differentiation
defects. Here we report that immature HSCs coex-
press c-myc and N-myc mRNA at similar levels. Al-
though conditional deletion of N-myc in the bone
marrow does not affect hematopoiesis, combined
deficiency of c-Myc and N-Myc (dKO) results in pan-
cytopenia and rapid lethality. Interestingly, prolifera-
tion of HSCs depends on bothmyc genes during ho-
meostasis, but is c-Myc/N-Myc independent during
bone marrow repair after injury. Strikingly, while
most dKO hematopoietic cells undergo apoptosis,
only self-renewing HSCs accumulate the cytotoxic
molecule GranzymeB, normally employed by the in-
nate immune system, thereby revealing an unex-
pected mechanism of stem cell apoptosis. Collec-
tively, Myc activity (c-Myc and N-Myc) controls
crucial aspects of HSC function including prolifera-
tion, differentiation, and survival.
INTRODUCTION
Long-term hematopoietic stem cells (HSCs) are defined by their
unique ability to self-renew while concomitantly differentiating to
generate all mature blood cell types. HSCs possess the clonal
capacity to provide life-long reconstitution of all hematopoietic
lineages upon transplantation into lethally irradiated mice (Pur-
ton and Scadden, 2007; Shizuru et al., 2005; Till and Mc Culloch,
1961). To therapeutically take advantage of the exclusive regen-
erative properties of LT-HSCs, it is fundamental to elucidate the
mechanisms by which these cells maintain the balance betweenCeself-renewal and differentiation. The advent of genetically
engineered mice has facilitated identification of several mole-
cules that play a role in stem cell maintenance and function.
For example, mice lacking signaling components such as TPO-
cMPL (Qian et al., 2007; Yoshihara et al., 2007), Ang1-Tie2
(Arai et al., 2004), or SCF-cKit (Thoren et al., 2008), or nuclear
regulators such as FOXO proteins (Tothova et al., 2007) or
Bmi-1 (Park et al., 2003), have impaired HSC function. Most
of these molecules participate in cell-cycle control, regulation
of apoptosis, and response to oxidative stress, or interact with
the surrounding niche environment (Orford and Scadden,
2008; Wilson and Trumpp, 2006). In HSCs, these processes
are tightly regulated, most likely through distinct mechanisms
during homeostasis or under stress conditions. For instance,
myeloablative chemotherapy transiently induces cell-cycle and
cell-surface marker changes in HSCs, allowing them to enter
an activated state in order to re-establish normal hematopoiesis
(Randall and Weissman, 1997; Venezia et al., 2004).
The Myc family members, c-Myc, N-Myc, and L-Myc (DePinho
et al., 1987), encode basic helix-loop-helix leucine zipper tran-
scription factors that are potent oncogenes. Myc proteins have
been implicated in many biological processes, such as prolifer-
ation, cellular growth, angiogenesis, apoptosis, differentiation,
and regulation of chromatin structure (Eisenman, 2001; Knoep-
fler, 2007; Murphy et al., 2005; Nilsson and Cleveland, 2003).
Moreover, c-Myc (or N-Myc) has been identified as an important
element in the induced reprogramming of adult fibroblasts into
embryonic stem cells like iPS cells (Knoepfler, 2008; Lewitzky
and Yamanaka, 2007). While many studies have shed light on
the mechanisms by which overexpression of Myc promotes
tumorigenesis (Pelengaris et al., 2002), its physiological role still
remains elusive in many tissues in vivo. While L-Myc appears
dispensable during development (Hatton et al., 1996), deletion
of c-myc or N-myc leads to embryonic lethality (Charron et al.,
1992; Dubois et al., 2008; Trumpp et al., 2001). We have previ-
ously reported that deleting c-myc in the adult bone marrow
(BM) via the inducible MxCre-loxP system unexpectedly results
in an accumulation of functionally defective HSCs (Wilson et al.,ll Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Inc. 611
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HSC Function and Survival Depend on Myc ActivityFigure 1. N-myc Is Highly Expressed in HSCs, but Its Conditional Deletion Does Not Impair Steady-State Hematopoiesis
(A and B) qRT-PCR assessment of the expression levels of c-myc,N-myc, and L-myc in selected bone marrow populations. LT-HSCs (LSK CD150+CD48CD34
and LSK CD150+CD48CD34+). Cell surface marker definition of the other populations is indicated in Table S1. (A) Relative expression of each gene after TBP
normalization. (B) Percent contribution of c-myc, N-myc, and L-myc to the total Myc pool in each population.
(C) Conditional deletion of c-myc and N-myc by pIpC treatment of MxCre;c-mycflox/flox;N-mycflox/flox mice. pIpC triggers IFNa production that, in turn, leads to
activation of the Mx promoter, which drives the Cre recombinase.
(D–F) Analysis of N-myc-deficient hematopoietic cells at homeostasis 5 weeks after pIpC treatment. (D) Total numbers of BM, thymus, or spleen cells in N-Myc-
deficient animals (Nmycfl/flCre+) compared to normal littermates (Nmycfl/flCre). (E) Total numbers of BM stem and progenitor cell populations LinSca-1+c-kit+
(LSK), LSK-SP, and LSK-CD150+CD48 (LSK-SLAM) and (F) of major BM differentiated cell types B cells (CD19+B220+), Myeloid cells (GR1+ and/or F480+),
Erythroid (Ter119+), and Megakaryocytes (CD41+GR1). Results are mean ± SD.2004). In the absence of c-Myc, differentiation of these cells into
more committed progenitors is inhibited as they upregulate
a number of adhesion molecules that anchor them in the niche,
thus preventing their differentiation. Surprisingly, and in contrast
to differentiated progenitors, c-Myc-deficient HSCs can still
divide, and their proliferation capacity is not affected. Since
N-myc is expressed in normal and c-Myc-deficient HSCs
(Ivanova et al., 2002; Wilson et al., 2004), we have genetically
addressed the individual role of N-Myc, as well as that of
c-Myc and N-Myc together, for HSC self-renewal, survival, and
differentiation.
RESULTS
Expression of c-myc, N-myc, and L-myc
in Hematopoietic Lineages
To address whether, in addition to c-Myc, other Myc family
members are involved in controlling HSC and progenitor612 Cell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Incfunction, the expression levels of c-myc, N-myc, and L-myc
were determined by qRT-PCR in various stem and progenitor
populations isolated by FACS (Figure 1A). Identical amplification
efficiencies for all three genes were established to not only quan-
titatively determine the expression of each gene, but also to
compare the relative amounts of each transcript expressed in
each individual cell type. Total myc mRNA levels (c- + N- +
L-myc) were found to be highest in the most immature HSCs
and progressively decreased during differentiation (Figure 1A).
While c-myc and N-myc are detected in most progenitor sub-
sets, L-myc only modestly contributes to the general Myc activity
in CLPs, megakaryocytes, and macrophages (3%–5% of total
Myc) and is not expressed in any stem/progenitor cells. The
highest expression levels of total myc transcripts are found in
the most immature HSCs (CD34 and CD34+LT-HSCs), where
c-myc andN-myc contribute approximately equal amounts. Dur-
ing the initial differentiation step into ST-HSCs, the total myc
level drops by approximately 30% but then remains constant.
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mostly due to the progressive decrease of N-Myc transcripts
while c-Myc mRNA expression remains stable. Surprisingly,
despite c-Myc being essential for proliferation of most differenti-
ated hematopoietic cell types, it is only expressed at modest
levels in mature cell types (Figures 1A and 1B). These data
show that expression of N-myc is essentially restricted to HSCs,
thus raising the possibility that in addition to c-Myc, N-Myc may
also play an important role in HSC function.
N-Myc Is Not Essential for Steady-State Hematopoiesis
To investigate the role of N-Myc during hematopoiesis, adult
MxCre;N-mycflox/flox mice were generated and treated with
pIpC to conditionally eliminate this gene in all hematopoietic
cell types, including HSCs (Figure 1C) (Knoepfler et al., 2002;
Ku¨hn et al., 1995). Five weeks postdeletion of N-myc, total num-
bers of cells in the BM, thymus, or spleen of mutant mice were
indistinguishable from those of control littermates (Figure 1D).
In addition, similar proportions of all major BM populations
(Figure 1F), including stem/progenitor cell types such as LSK,
LSK-SP (Side Population), or LSK-SLAM (LSK CD150+CD48)
populations (Figure 1E) were observed in control and mutant
mice. While deletion of N-myc was complete (Figure S1A avail-
able online), no significant compensatory upregulation of either
c-myc or L-myc was observed (data not shown). To address
whether N-Myc-deficient HSCs are functional, limiting dilution
assays in a competitive chimera setting were performed.
N-Myc-deficient BM cells were indistinguishable from control
BM cells in their capacity to engraft (>2% donor contribution
after 21 weeks) (Table S2). In summary, these data suggest that
deletion of N-myc alone has no major impact on HSC numbers
and does not affect the capacity to maintain adult hematopoiesis.
Simultaneous Elimination of Both c-Myc and N-Myc
Leads to Rapid Hematopoietic Failure, Including HSC
Loss
We have previously shown that c-Myc-deficient HSCs have a
severe niche-dependent differentiation defect, indicating that
c-Myc activity is required for proper HSC function. Interestingly,
c-Myc-deficient HSCs proliferate normally, suggesting that the
remaining N-Myc expression may be sufficient to maintain self-
renewing divisions in c-Myc null HSCs. Moreover, the fact that
both c-myc and N-myc transcripts are equally expressed in
HSCs raises the possibility that both genes control HSC self-
renewal and possibly other HSC functions in a cooperative or
additive manner. To genetically address this hypothesis,
MxCre;c-mycflox/flox;N-mycflox/flox double knockout (dKO) mice
were generated (Trumpp et al., 2001; Knoepfler et al., 2002).
Treatment of these mice with pIpC resulted in the loss of both
c-myc and N-myc transcripts from day 4 onward. Although dele-
tion of both c-myc and N-myc was very efficient (90% and 98%,
respectively) as measured by qRT-PCR, no significant (p = 0.28)
compensatory upregulation of L-Myc was observed in dKO BM
subsets (Figure S1B). Simultaneous deletion of c-myc and
N-myc rapidly induced severe pancytopenia (much faster than
after deletion of c-Myc alone; Wilson et al. [2004]), as dKO
mice died as early as 12 days after Cre induction (Figure 2A).
Just prior to death, dKO mice were severely anemic, and their
bone cavities were almost completely devoid of hematopoieticCecells, further confirming complete BM failure upon loss of both
genes (Figure 2C). Total BM cellularity rapidly decreased (>90%)
2 weeks postdeletion (Figure 2B). All major BM cell types, includ-
ing myeloid, lymphoid,and erythroidcells, wereprogressively lost,
albeit with distinct kinetics (Figure 2B and Figure S2A). Cell counts
in peripheral hematopoietic organs, such as spleen and peripheral
blood, were also strongly reduced in dKO animals (Figures S2B
and S2C). Collectively, these results show that simultaneous elim-
ination of c-Myc and N-Myc in the adult BM results in rapid hema-
topoietic failure and subsequent lethality 2 weeks postdeletion.
At the stem/progenitor level, the LSK compartment was no
longer recognizable in dKO mice as early as day 4 postdeletion
(Figure 2D, left panels). Instead, LinSca1+cKit cells accumu-
lated, suggesting that c-Kit expression is lost in mutant LSKs.
Downregulation of c-Kit cell surface expression on functional
HSCs has also been reported in response to 5-FU-induced mye-
losuppression. Such severe loss of myeloid cells is thought to
activate dormant HSCs, inducing them to cycle and generate
progenitors and new mature cells to quickly reachieve homeo-
stasis (Randall and Weissman, 1997; Wilson et al., 2008). Since
simultaneous loss of c-Myc and N-Myc results in a similar reduc-
tion of BM cells to that observed after treatment with 5-FU, HSCs
could still be present in dKO mice, but they would have also
downregulated surface expression of the cKit receptor by an
analogous mechanism. dKO BM was thus reanalyzed using
the SLAM receptors CD150 and CD48 (Kiel et al., 2005). As all
LinSca1+CD150+ cells in control mice are also cKit+, HSCs
can be phenotypically identified without cKit by analyzing the
LinSca1+CD150+CD48 population (hereafter called SLAM-
HSC). Around 40% to 60% of SLAM-HSCs are still present in
dKO mice shortly after deletion. However, their number steadily
declines over time, and almost all SLAM-HSCs are lost by day 8
postdeletion (Figure 2E). Relative and absolute numbers of
SLAM-HSCs in the spleen also decreased significantly (Fig-
ure S2D and data not shown), indicating that there was no sig-
nificant mobilization of dKO HSCs from the BM to this organ
and no subsequent extramedullary hematopoiesis. In summary,
these results demonstrate that simultaneous deletion of both
c-myc and N-myc results not only in rapid hematopoietic failure,
but also in the complete loss of phenotypic HSCs.
c-Myc;N-Myc Double-Deficient HSCs and Differentiated
Cells Display Aberrant Proliferation and Enter an
Apoptosis Program
To determine the effects of total loss of Myc activity on cellular
proliferation, the cell-cycle status of all major hematopoietic
populations, including HSCs, was determined in dKO animals
6 days after pIpC injection. As expected, a highly significant
reduction of cells in the S/G2/M phases of the cell cycle was
observed in the dKO myelomonocytic population (3-fold; p <
0.01; Figure 3A). In contrast, dKO SLAM-HSCs cycled signifi-
cantly more than control HSCs (4-fold; p < 0.001; Figure 3B).
To ensure that these unexpectedly proliferating HSCs had not
simply escaped deletion of either c-myc or N-myc, the prolifera-
tive BrdU+ populations of HSCs (LinSca1+CD150+BrdU+) from
control and dKO mice were isolated by FACS and analyzed by
immunofluorescence for the expression of c-Myc and N-Myc
proteins. While abundant expression of both c-Myc and N-Myc
was observed in more than 80% of control cells, HSCs isolatedll Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Inc. 613
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HSC Function and Survival Depend on Myc ActivityFigure 2. Simultaneous Deletion of c-myc and N-myc Results in Rapid BM Failure and Depletion of the HSC Pool
(A) Kaplan-Meyer survival curve of MxCre;c-mycflox/flox;N-mycflox/flox (dKO) mice after pIpC-induced deletion.
(B) Kinetic analysis of dKO BM cells relative to control mice from 4 to 16 days after the first pIpC injection. Days 4 and 6, n > 8; and days 14 and 16, n = 3. Data are
from at least two separate experiments per time point. Data represent mean ± SD.
(C) Hematoxylin-eosin staining of transversal sections of the femur trabecular zone 14 days after the first pIpC injection. 103 magnification. Control on the left;
dKO on the right.
(D) Representative FACS profiles of early hematopoietic stem/progenitor cells isolated from control and dKO mice 6 days after pIpC treatment (bottom). BM
cells were stained with Lineage, cKit (CD117), Sca1, CD150, and CD48 antibodies and gated as indicated. cKit+ Sca1+ labeling alone would erroneously predict
a complete loss of stem cells and early precursors (left panel). The use of the SLAM markers CD150 and CD48 shows that the dKO LinSca1+ compartment
downregulates cKit cell-surface expression (middle panel) but still contains a subset of HSCs (LinSca1+CD150+CD48, right panel).
(E) Quantification of the number of SLAM-HSCs post pIpC induction. Data are from at least two experiments per time point, 2 < n < 4 per genotype and time point.614 Cell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Inc.
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HSC Function and Survival Depend on Myc ActivityFigure 3. Simultaneous Deletion of c-myc and N-myc Affects Proliferation and Survival of Hematopoietic Cells in a Context-Dependent
Manner
(A and B) Cell-cycle status (DNA content; Hoechst 33342 staining) of control and dKO cells 6 days after pIpC treatment. Representative examples of granulocytic
(Gr1+CD11b+) cells (A) and of SLAM-HSCs (LinSca1+CD150+CD48) (B) are shown in the left panels. Mean percent of cells in S/G2/M phase (±SD) is shown in
the corresponding right panel. n = 3.
(C and D) c-Myc/N-Myc expression levels were determined by immunofluorescence on cytospins from FACS sorted BrdU+LinSca1+CD150+ cells. BrdU was
administered to the mice via the drinking water 15 hr prior to analysis. Representative pictures are shown in (C), with BrdU in green and c-Myc/N-Myc in red. Scale
bar, 20 mm. (D) c-Myc/N-Myc expression levels were blindly scored on two control and three dKO mice. A minimum of 25 cells per genotype was analyzed, and
each cell was assigned an intensity of Myc expression as exemplified in (C). Genetic controls for the antibodies used are presented in Figure S6.
(E–G) Quantitative analysis (FACS) of apoptosis (TUNEL) in the granulocyte (E), erythroblast (F), and SLAM-HSC (G) populations. Data represent mean ± SD,
n > 3 per time point.from dKO mice showed only very low or undetectable levels
of c-Myc or N-Myc protein, confirming that MxCre-mediated
deletion of both genes was highly efficient. These data
demonstrate that, surprisingly, dKO SLAM-HSCs are able to
proliferate even in the absence of both c-Myc and N-Myc
(Figures 3C and 3D).CeWe also analyzed whether an increase in the relative amount
of apoptosis occurred upon deletion of c-myc and N-myc by
performing TUNEL and AnnexinV analyses ex vivo and after
in vitro culture. dKO granulocytes, erythroblasts, and all B cell
stages except the most mature BM B cells (IgM+) showed a sub-
stantial increase in apoptosis from day 4 postdeletion onward,ll Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Inc. 615
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HSC Function and Survival Depend on Myc Activitywith a further increase by day 6 (Figures 3E and 3F and data not
shown). Moreover, increased cell death was also observed in the
dKO LT-HSC (LinSca1+CD150+CD48CD34) population as
early as 4 days after the first pIpC injection (Figure 3G). Apopto-
sis was also induced in cultured mutant progenitors upon MxCre
induction by IFNa, indicating that cell death induced by the loss
of c-Myc and N-Myc is likely to be cell-autonomous and is not
a result of putative alterations of the stem cell environment (Fig-
ure S3A). In addition to TUNEL assays, AnnexinV/7AAD analysis
independently confirmed these results (data not shown). In sum-
mary, most of the major hematopoietic lineages, including HSCs,
undergo apoptosis within a few days of the simultaneous loss of
c-myc andN-myc. This not only provides a plausible explanation
for the rapid general BM failure, but also reveals that while
the presence of either N-Myc or c-Myc alone ensures survival,
hematopoietic cells lacking both proteins are quickly lost due
to cell death.
Bone Marrow Failure upon Loss of c-Myc and N-Myc
Is Hematopoietic Cell Autonomous
The MxCre transgene induces significant deletion also outside
the hematopoietic system, including the BM stromal compart-
ment and the liver (Ku¨hn et al., 1995). Nevertheless, c-myc and
N-myc deletion in nonhematopoietic cell types does not contrib-
ute to the severe phenotype observed, as all the defects
described above for dKO mice could be qualitatively and quan-
titatively recapitulated in noncompetitive BM transplantation
experiments in which the c-myc and N-myc genes were deleted
after reconstitution (Figure S4A).
To determine the functional capacity of dKO HSCs in a com-
petitive situation, competitive BM transplantation experiments
were performed (Figure 4A). CD45.2+ recipient mice were lethally
irradiated and reconstituted with either a 1:1 or a 3:1 mixture
of experimental, but not yet deleted, BM cells (MxCre;
c-mycflox/flox;N-mycflox/flox;CD45.1+/2+) together with nondelet-
able control (c-mycflox/flox;N-mycflox/flox;CD45.2+) cells (mixed
chimeras). After stable reconstitution was established, deletion
of both myc genes was induced by pIpC and the BM analyzed
14 or 21 days later (Figure 4A). In this set-up, the nondeletable
control (‘‘wild-type’’) cells maintain hematopoiesis even if the
dKO cells are lost after pIpC treatment and, therefore, prevent
the development of a severe BM phenotype. This strategy con-
veniently permits differentiation between cell autonomous ef-
fects due to loss of c-Myc and N-Myc, and any effects secondary
to the severe BM cytopenia that occurs in dKO mice and non-
mixed chimeras. As expected, these competitive chimeric
mice did not appear anemic upon deletion and had normal total
BM cell numbers (data not shown). However, dKO donor cells
were specifically lost as their relative chimerism decreased by
70% on day 14 and 90% 21 days after the first pIpC injection
(Figure 4B). Furthermore, dKO donor cells proliferated signifi-
cantly less compared to control cells and displayed increased
apoptosis (Figure S5), in agreement with the results observed
in dKO mice and nonmixed chimeras. In summary, these data
show that dKO BM cells are lost even in a wild-type microenvi-
ronment (competitive and noncompetitive chimeras) and are
unable to compete with wild-type hematopoietic cells in
a steady-state (mixed BM chimera) or cytopenic (dKO and non-
competitive transplantation) situation.616 Cell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier InRole of Myc Proteins in HSC Proliferation and Survival
during Homeostasis and Stress Response
In contrast to dKO mice and nonmixed chimeras, no downregu-
lation of cKit cell surface expression was observed in dKO
SLAM-HSCs in mixed chimeras (Figure 4C). Since these animals
are not anemic, these data confirm that loss of cKit expression in
dKO mutants is a secondary consequence of the BM hypoplasia
similar to what is observed after 5-FU-induced BM ablation
(Randall and Weissman, 1997) and is not a direct effect of
Myc activity on c-Kit expression or cell-surface localization.
Importantly, significant numbers of dKO SLAM-HSCs were still
present in competitive chimeras. In comparison to their initial
numbers before deletion, the total number of dKO SLAM-
HSCs (LSKCD150+CD48) had only halved by day 14 after dele-
tion and only further decreased to 25% by day 21 (Figure 4E),
a rather modest reduction compared to dKO mutants where all
HSCs are lost within 8 days (Figure 2E). Analysis of the propor-
tion of apoptotic cells in mixed chimeras revealed that in contrast
to Lin progenitors in which apoptotic rates are normal, dKO
HSCs displayed a 2.5-fold increase in cell death compared to
control cells (Figure 4F), highly similar to the situation in dKO mu-
tant mice (Figure 3G). However, in striking contrast to HSCs in
dKO mice, which show increased proliferation, the percentage
of actively cycling dKO SLAM-HSCs (%S/G2/M) in mixed BM
chimeras was strongly reduced compared to controls (3-fold;
p < 0.001; Figure 4G). These results suggest that c-Myc and
N-Myc are indeed critical for the proliferation of HSCs, but only
during homeostasis (mixed BM chimeras) and not in situations
of severe BM stress (dKO animals). This result supports the no-
tion that Myc-dependent and Myc-independent HSC prolifera-
tion programs can be engaged during homeostasis and repair.
Proliferating Cells with HSC Phenotype Are More
Dependent on Myc Activity Than Quiescent HSCs
To investigate whether c-Myc- and N-Myc-deficient HSCs retain
any long-term repopulation ability, serial transplantations
were performed. BM from the primary competitive chimeras
described above was harvested 14 days after pIpC treatment
and transferred into lethally irradiated (CD45.2+) recipients and
analyzed 12 weeks later (Figures 5A and 5B). As expected, no
contribution from dKO-deficient cells to either the myeloid or
erythroid compartments was observed (Figure 5B and data not
shown), showing that no stem cell activity is retained in dKO
SLAM-HSCs. Nevertheless, dKO SLAM-HSCs were still present
in secondary recipients although their number had decreased
about 6-fold compared to that at the time of transfer (Figure 5C).
These results demonstrate that although HSCs lacking c-myc
and N-myc can be serially transplanted, they do not give rise
to differentiated progeny and, thus, have lost one of the critical
features of stem cells.
The persistence of dKO dormant/quiescent HSCs indicates
that these cells are less susceptible to the loss of bothmyc genes
compared to actively proliferating HSCs. To test this hypothesis,
a ‘‘label-retaining cell’’ experiment (LRC; Arai et al., 2004; Wilson
et al., 2008) that permits distinction between quiescent and self-
renewing stem cells, was performed on mixed chimeras to mon-
itor the outcome of c-Myc/N-Myc deletion on long term dormant
HSCs while avoiding putative cytopenia-induced effects
(Figure 5D). After elimination of both myc genes, about 60% ofc.
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HSC Function and Survival Depend on Myc ActivityFigure 4. Bone Marrow Failure in dKO Mice Is Hematopoietic Autonomous, and dKO HSCs Show Decreased Proliferation and Survival
(A) Competitive bone marrow chimeras. Mice were reconstituted with equal amounts of c-mycflox/flox;N-mycflox/flox cells and undeleted MxCre;c-mycflox/flox;
N-mycflox/flox BM cells. After stable engraftment (8 weeks), pIpC was administered to the mice to induce deletion. The chimeras were analyzed 14 or 21 days
after the first pIpC injection.
(B) Kinetics of loss of donor dKO cells in mixed chimeras. Results are mean ± SD. D14, n = 8; D21, n = 3.
(C) dKO HSCs present in mixed chimeras do not downregulate cKit (CD117) cell-surface expression. BM from competitive chimeras 14 days after pIpC treatment
was analyzed and gated on LinSca1+CD150+CD48. The expression levels of cKit in the CD45.2+ (WT) rescue and in the CD45.1+/2+ (dKO) population were
compared. Representative FACS plots from a total of six mice are shown.
(D) Degree of relative chimerism on progenitor and stem cell populations. CLPs (LincKitintSca1int CD127+), CMPs (LincKit+Sca1); n > 3.
(E) Degree of relative chimerism of SLAM-HSCs. Triangles, individual mice; horizontal bar, the mean value for each genotype. D14, n = 8; D21, n = 3.
(F) Chimeras 14 days after the first pIpC treatment: BM was stained with stem cell markers, and apoptosis was assessed by TUNEL using FACS. Mean ± SD is
shown; n = 3.
(G) Chimeras 14 days after the first pIpC treatment were administered BrdU for 15 hr before percent BrdU incorporation was assessed. Mean ± SD is shown; n = 3.the self-renewing SLAM-HSCs (BrdU), but none of the dKO
LRC SLAM-HSCs, were lost 14 days after the first pIpC injection
(Figure 5E). These results indicate that during homeostasis, de-
letion of both c-myc and N-myc rather modestly, if at all, impairs
maintenance of the quiescent, and therefore most immature,
HSCs but strongly affects self-renewal and survival capacities
of activated HSCs. Thus, Myc activity becomes critical duringCethe activation process promoting quiescent HSCs into a self-
renewal mode.
Myc Depletion Results in Upregulation of Granzyme B
Expression in HSCs
HSC survival can be increased by expression of the antiapop-
totic factor BCL-2 (Domen and Weissman, 2000) and can bell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Inc. 617
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HSC Function and Survival Depend on Myc ActivityFigure 5. Proliferating HSCs, but Not Quiescent HSCs, Are Preferentially Lost in dKO Mice
(A) Secondary transplantation. BM from primary transplanted mice was harvested 14 days after deletion (see Figure 4A) and transferred into lethally irradiated
CD45.2+ hosts. Percent CD45.1+/2+ myeloid cells (B) or SLAM-HSCs (C) in BM of secondary transplanted recipients 84 days after transplantation. (D) Label-
Retaining Cell (LRC) assay. Undeleted mixed chimeric mice were administered BrdU in their drinking water for 10 days, followed by 70 days of chase (no
BrdU). During the chase period, rapidly dividing cells dilute out the BrdU label, while long-lived quiescent cells (among which are dormant HSCs) retain this
marker. Deletion was induced so that the day of analysis corresponded to both 70 days of chase and 14 days after the first pIpC injection. (E) BM from LRC
mice was isolated and stained for stem cell markers. Relative chimerism (mean ± SD) of BrdU or BrdU+ SLAM-HSCs is shown. n = 3.strongly inhibited by an increase in Reactive Oxygen Species
(ROS) (Ito et al., 2006; Tothova et al., 2007). While overexpres-
sion of BCL-2 (via the H2K-BCL-2 transgene) rescued apoptosis
in dKO B lymphocytes, it did not diminish the apoptosis rate of
SLAM-HSCs, nor did it rescue their rapid decline in numbers
(Figure 6A and data not shown). To test whether the apoptosis
induced upon loss of c-Myc and N-Myc in HSCs is mediated
by upregulation of ROS, the intracellular concentration of ROS
in dKO SLAM-HSCs was determined by DCF-DA staining. How-
ever, no significant differences could be detected between con-
trol and dKO SLAM-HSCs (Figure 6B), indicating that apoptotic
cell death of dKO HSCs is not mediated by an increase in ROS.
To elucidate the mechanisms underlying apoptosis of dKO
HSCs, the global gene expression profiles of FACS-purified
SLAM-HSCs and committed progenitors isolated from control
and dKO mice were established using Affymetrix arrays
(Figure 6C). As expected, c-myc and N-myc transcripts were
strongly downregulated while L-myc expression was not618 Cell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Insignificantly changed, in agreement with the data obtained by
qRT-PCR (Figure S1B). In addition, dKO HSCs showed higher
mRNA levels of the gene encoding the CDK inhibitor p21CIP,
which is known to be repressed by c-Myc (Oskarsson et al.,
2006; Wu et al., 2003). An HSC signature was generated by com-
paring the global gene expression profiles of wild-type LT-HSCs
and progenitors. The expression of genes present in this
wild-type HSC signature was only marginally changed in dKO-
SLAM-HSCs, indicating that no significant loss of stem cell
identity occurs upon loss of Myc activity (data not shown). This
is consistent with our finding that the most quiescent dKO
HSCs are maintained. Interestingly, the expression of 31 genes
encoding ribosomal proteins was significantly downregulated
(Figure S3), suggesting that ribosome biogenesis is strongly in-
hibited as a result of c-myc and N-myc gene loss. Intriguingly,
the most upregulated transcript upon loss of both Myc family
members was the gene encoding for Granzyme B (GrB, 150-
fold and 130-fold as determined by microarray and qRT-PCRc.
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HSC Function and Survival Depend on Myc ActivityFigure 6. c-Myc and N-Myc Promote Survival of HSCs and Prevent GrB Accumulation
(A) Absolute numbers, relative to control mice, of SLAM-HSCs in dKO and H2K::BCL2 dKO mice, 6 days after pIpC treatment. Mean ± SD is shown; nR 3.
(B) SLAM-HSCs from dKO and control animals were stained with DCF-DA to measure the intracellular concentration of ROS. A representative FACS plot is
shown; n = 3.
(C) Differential expression levels of selected genes as analyzed by microarray analysis 4 days after the first pIpC injection.
(D) Intracellular FACS staining to determine expression of Granzyme B (GrB) protein (blue line, control; red line, dKO; tinted, isotype control; nR 3 for each condition).
(E) Quantification of GrB expression at day 4 and day 6. Percent GrB+ in gated LinSca1+CD150+CD48 cells. The Lin cocktail includes DX5, NK1.1, CD3, CD4,
and CD8 antibodies in order to eliminate any possible contamination from canonical GrB-producing cells, such as CTLs and NK cells. Blue triangles, individual
control mice; red circles, dKO mice. Horizontal bars indicate averages of at least 6 mice per genotype.
(F) Intracellular GrB staining on indicated cell types 4 days after pIpC treatment.
(G) Representative GrB expression profiles gated on LSKCD150+CD48 in mixed chimeras (left panel) and in cultured SLAM HSCs 48 hr after IFNa addition.
(H) Representative pictures of GrB by immunofluorescence. Lin cells or activated NK cells (DX5+, positive control) were cytospun onto slides and stained for GrB
protein and DAPI (blue). Scale bar, 5 mm.
(I–K) GrB/TUNEL double staining on gated LinSca1+CD150+CD48 cells at 4 and 6 days after c-myc andN-myc deletion. (I) Representative FACS plots at day 6.
(J and K) Quantification of percentage of GrB+ cells among TUNEL+ SLAM HSCs ([J], mean ± SD) and of TUNEL+ cells among GrB+ SLAM HSCs (K). Day 4, n = 3;
day 6, n = 2 for controls and n = 5 for dKO.Cell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Inc. 619
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HSC Function and Survival Depend on Myc Activityanalysis, respectively; Figure 6C and Figure S7A), a highly potent
cytotoxic molecule. The serine-protease Granzyme B plays
a key role in the granule-exocytosis pathway, which is used by
activated cytotoxic T lymphocytes (CTLs) and natural killer
(NK) cells to eliminate cells infected with intracellular pathogens
or tumor cells (Russell and Ley, 2002). Normal SLAM-HSCs do
not express GrB as determined by intracellular FACS staining
(Figures 6D and 6E; Revell et al., 2005). In contrast, most dKO
SLAM-HSCs show highly elevated levels of intracellular GrB
protein (Figures 6D and 6E). Strikingly, GrB upregulation upon
c-myc and N-myc deletion is specific to HSCs since no in-
creased GrB could be detected in any other dKO hematopoietic
cell type (Figure 6F). Importantly, GrB is also upregulated in dKO
HSCs present in mixed chimeras (Figure 6G, left panel), and
deletion of both Myc genes in cultured progenitors in vitro also
resulted in the upregulation of intracellular GrB protein
(Figure 6G, right panel), indicating a cell-autonomous effect of
Myc deficiency on GrB production.
Processing of an N-terminal propeptide by the protease
cathepsin C (or DPPI) is required for the proteolytical activity of
GrB (Caputo et al., 1993; Pham and Ley, 1999). Cathepsin C
transcripts are significantly upregulated (2.5-fold) in dKO
SLAM-HSCs, while the expression level of the principal GrB
inhibitor, Serine Protease Inhibitor 6 (Spi-6), is unchanged
(Figure 6C and Figure S7A). Several groups have recently re-
ported GrB-leakage-induced cell death in NK cells and CTLs,
in which functionally active GrB escapes into the cytoplasm,
thus provoking apoptosis of the GrB producing cell itself. The
major determinant of such endogenous GrB-mediated killing
seems to be an excess of free active GrB over its cytoplasmic in-
hibitor Spi-6 (Ida et al., 2003; Laforge et al., 2006; Phillips et al.,
2004; Zhang et al., 2006), which correlates with diffuse cytoplas-
mic localization of the GrB protein. In agreement with this notion,
in the vast majority of dKO progenitor cells (70.3% ± 0.4), GrB
protein is located throughout the cytoplasm (diffuse pattern,
Figure 6H, bottom panels, Figure S7B), in sharp contrast to the
specifically localized and punctuate pattern observed in most
(85.1% ± 2.0) activated NK cells (Figure 6H, top right panel;
Figure S7B). All conditions for cell-autonomous killing by GrB
are thus met in dKO HSCs. To assess whether GrB+ dKO
HSCs are indeed dying as a consequence of GrB upregulation,
HSCs were simultaneously assayed for TUNEL and GrB expres-
sion (Figures 6I–6K). Around 80% of dying dKO SLAM-HSCs
were also GrB+ (Figure 6J). Moreover, the percentage of TUNEL+
cells among GrB+ dKO SLAM-HSCs increased over time, from
about 40% at day 4 to around 70% at day 6 post-pIpC injection
(Figure 6K), indicating that GrB upregulation precedes HSC ap-
optosis. Taken together, our results suggest that Myc depletion
results in the massive increase of catalytically active GrB in
SLAM-HSCs. As GrB is one of the most toxic molecules known,
we conclude that Myc activity is required to ensure stem cell
survival via repression of Granzyme B, thus identifying an unex-
pected mechanism of HSC apoptosis.
DISCUSSION
In this paper, we show that c-myc andN-myc are coexpressed in
the most immature hematopoietic stem-progenitor populations
and provide genetic evidence that total Myc activity (c-Myc,620 Cell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier InN-Myc, and L-Myc) controls HSC function at various levels (Fig-
ure 7). We demonstrate that c-Myc and N-Myc are required for
HSC proliferation, metabolic growth, differentiation, long-term
self-renewal activity, and survival of stem cells by inhibiting
GrB-mediated apoptosis.
c-myc and N-myc Are Coexpressed in HSCs,
and Both Contribute to Stem Cell Function
Our analysis of the precise expression pattern of the Myc family
members throughout hematopoiesis has led to a number of
important observations. First, no hematopoietic cell type ex-
presses only N-myc or L-myc without c-myc. Consistent with
the genetic data discussed below, this suggests that c-Myc pro-
vides the baseline Myc function in hematopoietic cells. The addi-
tional expression of either or both of the other two myc genes
through their distinct regulatory regions is likely to fine-tune total
Myc activity in these cell types. Second, the striking coexpres-
sion of c-myc and N-myc in immature HSCs combined with
the rapid decrease of N-myc (but not c-myc) transcripts at the
onset of HSC differentiation suggests that N-Myc plays a critical
role in HSC function. However, when ablated in the presence of
c-Myc, N-myc is dispensable for stem cell maintenance during
steady-state conditions or following stress accompanied by
transplantation (Figure 7C and Table S2). In contrast, when
N-myc is deleted in the absence of c-Myc (dKO situation), HSC
proliferation, survival, and differentiation are severely impaired
(Figures 7D and 7E). As deletion of c-myc alone (Figure 7B)
does not alter HSC proliferation and survival rates (Wilson
et al., 2004), our dKO data reveal a role for N-myc expression
in sustaining the survival and proliferation of c-myc null HSCs.
Moreover, no compensatory upregulation of one family member
is observed upon deletion of the other, implying that whenN-myc
is deleted, the unchanged c-myc transcript levels are sufficient
for maintaining all aspects of HSC maintenance. In addition,
when c-myc is deleted, the normally equivalent levels of N-myc
transcripts can provide enough Myc activity to ensure HSC
survival and proliferation but are not sufficient to permit exit
from the niche and differentiation past the ST-HSC stage (Wilson
et al., 2004). How can we explain such a discrepancy? Gene-
replacement studies in which the coding sequences and inter-
vening intron of c-myc were replaced by those of N-myc (NCR
allele) exclude the possibility that the N-Myc protein functionally
differs from c-Myc, since mice homozygous for this NCR allele
are viable and produce normal proportions of all differentiated
cell types (Malynn et al., 2000). Our own analysis of NCR BM
confirms these data as no obvious differentiation defect in their
HSC and progenitor compartments was detectable (data not
shown). Thus, N-Myc, if expressed in the exact pattern as en-
dogenous c-Myc, can provide all c-Myc functions during
steady-state hematopoiesis, including exit of HSCs from the
niche. Nevertheless, it remains possible that c-Myc and N-Myc
activities are quantitatively different in stem cells as a number
of studies have reported that N-Myc transactivation properties
are weaker than those of c-Myc (Cole and McMahon, 1999;
Malynn et al., 2000). Alternatively, differential posttranscriptional
regulation of c-Myc and N-Myc degradation may result in a pre-
dominance of c-Myc over N-Myc at the protein level in HSCs
(Zhao et al., 2008). Further experiments will be required to
address these appealing aspects.c.
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HSC Function and Survival Depend on Myc ActivityFigure 7. A Model for the Consequences of Loss of Myc in the Hematopoietic System
(A) Schematic representation of steady-state hematopoiesis in a normal mouse. The HSC compartment comprises both self-renewing HSCs that contribute to
day-to-day hematopoiesis and dormant HSCs that are only activated upon injury. N-myc expression levels contribute significantly to the Myc pool only in the
most primitive HSCs. All other hematopoietic cell types are predominantly controlled by the c-Myc homolog.
(B) Upon loss of c-myc alone (Wilson et al., 2004), HSCs are unable to differentiate into progenitors. However, the presence of N-Myc allows them to maintain their
self-renewal capacity, resulting in HSC accumulation in the bone marrow niche. The majority of early and late progenitors stop proliferating.
(C) In the presence of c-Myc, elimination of N-myc does not impact steady-state hematopoiesis.
(D and E) Deletion of both c-myc andN-myc reveals that c-Myc and N-Myc are crucial to promote survival throughout the hematopoietic system, as Myc-deficient
self-renewing HSCs accumulate GrB and rapidly die. When no wild-type cells are present (‘‘straight’’ dKO situation) (D), the rapid cell death of most differentiated
cell types induces pancytopenia. As a consequence, a positive-feedback loop is generated, leading to activation of dormant HSCs. In the absence of c-Myc and
N-Myc, self-renewing HSCs enter apoptosis and are therefore rapidly exhausted. In mixed chimeras (E), pancytopenia does not occur due to the presence of
wild-type cells. Thus, no feedback loop is generated and dKO-dormant HSCs are maintained.A third interesting observation is that total myc expression
peaks in the most immature HSCs and decreases in progenitors
and more mature cell types. Thus, absolute myc transcript levels
positively correlate with multipotency and self-renewal activity.
These results are consistent with reports suggesting Myc
genes as stem cell markers (Bettess et al., 2005; Cartwright
et al., 2005; Ivanova et al., 2002; Knoepfler et al., 2006;
Ramalho-Santos et al., 2002). Moreover, although not absolutely
required, c-Myc or N-Myc have been shown to participate in
reprogramming tail-tip fibroblasts into iPS cells, multipotent cells
highly similar to ESCs (Lewitzky and Yamanaka, 2007). The
mechanism by which Myc activity promotes this reprogramming
remains hypothetical, but its positive effects on cell-cycle and
metabolic growth, as well as its recently uncovered effect on
chromatin structure, have been suggested to be causally in-
volved (Knoepfler, 2008). Our study confirms that Myc activity
is critical for stem cell maintenance as total loss of Myc strongly
affects both self-renewal division and survival of activated HSCs,
suggesting that Myc expression is tightly regulated in order to
balance scheduled differentiation with maintenance of a rarely
self-renewing stem cell pool.
Interestingly, deletion of c-myc and N-myc in more committed
progenitors (Lin) severely diminishes their proliferation capac-
ity but does not compromise their survival, indicating that in
highly cycling progenitors (in contrast to HSCs), Myc principally
controls proliferation rates. Similarly, most lineage committed
cells (Lin+) are exquisitely sensitive to c-Myc levels as they
undergo G0 arrest after elimination of c-Myc (Trumpp et al.,Ce2001; Wilson et al., 2004). Collectively, our data show that prolif-
eration of most hematopoietic cell types, including homeostatic
HSCs, is Myc dependent. Nonetheless, we also provide
evidence that dKO HSCs retain their ability to rapidly cycle in re-
sponse to injury signals. Indeed, simultaneous deletion of c-myc
and N-myc in a noncompetitive setting causes severe pancyto-
penia due to cell-cycle exit and apoptosis of lineage committed
cell types. As a consequence, dKO stem cells become
‘‘activated’’ in order to repair the injured BM (like 5-FU treated
HSCs) (Randall and Weissman, 1997; Venezia et al., 2004).
This is accompanied by downregulation of c-Kit cell-surface ex-
pression and enhanced proliferation (Figure 7D). Since this pro-
liferative burst occurs without upregulation of the barely detect-
able L-myc transcripts, our data strongly suggest that situations
exist where hematopoietic cell cycling can occur in a Myc-inde-
pendent manner. In agreement with recent gene-profiling stud-
ies (Venezia et al., 2004), this observation implies that different
proliferation/self-renewal programs control HSC cycling during
homeostasis or in an injury response situation. Importantly, the
injury-activated and proliferating dKO HSCs all undergo apopto-
sis, leading to the complete loss of all HSCs in the ‘‘straight’’ mu-
tants. In contrast, in competitive chimeras where no cytopenia
(injury) develops, quiescent dKO HSCs are maintained, suggest-
ing that the loss of the Myc-mediated apoptotic response is
linked to an activated self-renewal program (Figure 7). In conclu-
sion,myc genes appear to be both critical and pleiotropic control
elements regulating not only homeostatic HSC cycling, but also
other key stem cell functions such as differentiation and survival.ll Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Inc. 621
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a GrB-Mediated Apoptosis Pathway
GrB, one of the most toxic proteases known, is, so far, only
thought to be produced by NK cells and CTLs, major compo-
nents of the innate immune system. NK cells possess finely
tuned production, shuttling, and targeting pathways that permit
delivery of GrB granules to target cells without any self-inflicted
damage. Here we demonstrate that the vast majority (80%) of
apoptotic dKO HSCs express significant levels of intracellular
GrB protein. Although GrB expression has not yet been reported
in murine stem cells, GrB expression has been observed in
human CD34+ cells after challenge with a combination of chemo-
therapeutic drugs and G-CSF (Berthou et al., 1995). As no
increase in Spi-6, which not only inactivates GrB proteolytic
activity but also contributes to its compartmentalization into exo-
cytic granules (Sun et al., 1997; Zhang et al., 2006), is detected
upon loss of both myc genes, HSCs are unlikely to be equipped
with the molecular machinery necessary to compartmentalize
GrB and/or counteract its devastating proteolytic effects. As
a consequence, aberrant production of GrB is most likely
the main cause of cell death of Myc-deficient HSCs, thus
revealing a previously unrecognized mechanism of stem cell
apoptosis.
Importantly, GrB accumulation is restricted to the stem cell
compartment. However a variety of other cell types undergo ap-
optosis in the absence of Myc, implying that distinct apoptotic
pathways are elicited in different Myc-deficient cellular contexts.
Indeed, our results suggest that BCL2 overexpression rescues
apoptosis in lymphoid cells at different stages of maturation,
but not in HSCs or in myeloid cells. Moreover, granulocytic cells,
but not HSCs or lymphoid cells, show upregulation of ROS (data
not shown). Although it is possible that Myc directly controls cell-
type-specific antiapoptotic target genes, it seems more likely
that the total absence of Myc activity generates a general cellular
emergency situation that then secondarily elicits a cell death pro-
gram inherent to each hematopoietic cell type. Our microarray
profiling data have revealed the downregulation of 31 different ri-
bosomal proteins in dKO HSCs, consistent with previous reports
showing that Myc controls transcription mediated by all three
RNA polymerases (Oskarsson and Trumpp, 2005). An interesting
possibility is that the absence of all Myc activity results in the
inability of dormant HSCs to increase protein biosynthesis
upon activation/stress signals. This metabolic/growth impair-
ment might in turn trigger GrB-mediated apoptosis. This is con-
sistent with our finding that the most quiescent/dormant HSCs,
in which protein metabolism is naturally low compared to actively
self-renewing HSCs (Passegue et al., 2005; Wilson et al., 2008),
are significantly less affected by simultaneous c-myc and N-myc
deletion than activated HSCs. Future experiments will address
whether induction of GrB accumulation in dKO HSCs is due to
their inability to grow in the absence of Myc, combined with
activating/stress signals caused by the resultant severe cytope-
nia or by pI-pC/IFNa treatment that also activates quiescent
HSCs in vivo (M.A.G. Essers, S. Offner, W.E.B.-B., Z. Waibler,
U. Kalinke, M.A. Duchosal, and A.T., unpublished data).
Collectively, our genetic data not only show that the absolute
Myc levels resulting from the combined expression of the c-myc
and N-myc genes are critical for several biological functions of
HSCs, but also identify GrB as a novel pathway used to eliminate622 Cell Stem Cell 3, 611–624, December 4, 2008 ª2008 Elsevier Indefective stem cells in vivo and may raise new possibilities to
target malignant cells including leukemic stem cells.
EXPERIMENTAL PROCEDURES
Conditional Deletion of c-myc and N-myc
Six- to twelve-week-old N-mycflox/flox (±MxCre) or c-mycflox/flox N-mycflox/flox
(±MxCre) mice were used throughout our study (Knoepfler et al., 2002; Trumpp
et al., 2001). Deletion of the flox alleles was induced with pIpC treatment
(Invitrogen). Control and experimental littermate mice were injected i.p. (up
to five times) every 2 days with 10 mg/g mouse (or 1 mg/g mouse in competitive
transplantation settings). For day 4 analyses, two injections on 2 consecutive
days were performed at 5 mg/g mouse.
Flow Cytometry and Purification of HSCs
BM was taken from hindlegs, forelegs, and/or backbone. Single-cell suspen-
sions were made by crushing bones after removal of muscle and connective
tissue. For a complete list of antibodies used, refer to the Supplemental Data.
Transplantation Assays
In the noncompetitive setting, 5 3 106 Thy1 depleted CD45.2+ c-mycflox/flox
N-mycflox/flox ± MxCre were injected i.v. into CD45.1+ lethally irradiated (900
rads in two doses of 450 rads 4 hr apart) recipient mice that had been treated
with 100 mg anti-NK1.1 mAb 24 hr beforehand. Similarly, in the competitive
setting, a mixture of 3 3 106 Thy1-depleted CD45.1/2+ c-mycflox/flox
N-mycflox/flox ± MxCre and 3 3 106 Thy1 depleted competitive wild-type BM
(c-mycflox/flox N-mycflox/flox ; CD45.2+) was i.v. transferred into CD45.2+ lethally
irradiated recipient animals. Mice were maintained on antibiotic (Bactrim,
Roche, Basel, Switzerland)-containing water for 3 weeks and reconstitution
of peripheral blood, BM, and spleen was analyzed at the indicated time points.
Limiting dilution experiments are described in the Supplemental Data.
BrdU Uptake and Label-Retaining Cell Assays
In vivo 5-Bromodeoxy-uridine (BrdU, Sigma) labeling was performed by inject-
ing control and experimental mice with 200 ml (1.8 mg BrdU/ml) i.p. then giving
water containing 1 mg/ml BrdU and 5% glucose for 15 hr. For the LRC assays,
control and experimental mice not yet treated with pIpC were maintained on
1 mg/ml BrdU and 5% glucose drinking water for 10–14 days, then on normal
water for the entire period of chase (70 days). In both assays, BrdU staining
was quantitated by FACS, combining staining of adequate cell surface
markers with BrdU intracellular staining using the BrdU-APC staining kit
according to the manufacturer’s instructions (BD Biosciences).
c-Myc/N-Myc Immunofluorescence
Experimental and control mice were labeled with BrdU for 15 hr as described
above. Following BM isolation and depletion of Lin+ cells, cells were stained
with CD150-APC and Sca1-biotin antibodies. Secondary staining was per-
formed with a SAV-APCCy7 conjugate. BrdU intracellular staining was carried
out using a BrdU-FITC staining kit (BD Biosciences). LinSca1+CD150+BrdU+
cells were then sorted on a FACS Aria Flow Cytometer (BD) and finally spun on
slides with a cytocentrifuge. c-Myc/N-Myc immunofluorescent staining was
performed as described in Figure S6.
Cell-Cycle Analysis
Cell-cycle analysis was performed by surface staining to define BM subsets,
followed by fixation and permeabilization with Cytofix/Cytoperm (BD
Biosciences). Intracellular staining with Hoechst 33342 (Molecular Probes,
Invitrogen) was done in Permwash (BD Biosciences) for 30 min.
Apoptosis Assays
Following cell surface staining, cells were incubated with 7-AAD and
AnnexinV-Cy5 (BD Biosciences) following the manufacturer’s instructions.
TUNEL labeling by FACS was performed with the in situ cell death detection
kit (Roche) according to the manufacturer’s protocol.c.
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HSC Function and Survival Depend on Myc ActivityDetermination of Intracellular Reactive Oxygen Species
BM samples prestained for the cell-surface markers of interest were loaded
with 5 mM DCF-DA (Sigma), incubated on a shaker for 30 min at 37C, and
then immediately analyzed on a FACS Canto instrument (BD).
GrB Intracellular Staining
For FACS analyses, total BM or Lin cells were stained for surface markers and
intracellular GrB as described (Revell et al., 2005) with a directly conjugated
GrB-PE antibody (CalTag, Invitrogen). Mouse IgG1-PE was used as the appro-
priate IgG control. For immunofluorescence assays, Lin cells were fixed in
3.7% PFA, then cytospun onto slides. Following permeabilization in PBS +
0.2% Triton X-100 and blocking with PBS + 15% Goat Serum, the slides
were stained overnight with anti-murine GrB biotinylated Ab (R&D Systems),
then for 1 hr with SAV-Alexa 568. Nuclei were counterstained with DAPI.
Microarray Analysis and RT-PCR
Total RNA isolation was performed from the indicated populations with TRizol
reagent (Invitrogen) according to the manufacturer’s instructions. Microarray
analysis raw data are available for download from Gene Expression Omnibus
(http://ncbi.nlm.nih.gov/geo; gene accession number: GSE12538). Microarray
and real-time PCR protocols are described in the Supplemental Data.
Statistical Analysis
All analyses were performed using two-tailed t tests assuming equal variance.
Statistical significance is indicated by *p < 0.1, **p < 0.05, and ***p < 0.01.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, seven figures, and three tables and can be found
with this article online at http://www.cellstemcell.com/supplemental/S1934-
5909(08)00458-X.
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